Accumulating evidence from genome-wide analysis and functional studies has begun to unveil the important role of long non-coding RNAs (lncRNAs) in cancer development. The lncRNA SPRY4-IT1 is derived from an intron of SPRY4 gene and was originally reported to be upregulated in melanoma in which it functioned as an oncogene.
| INTRODUC TI ON
Only ~2% of the human genome is transcribed into RNAs that encode proteins, whereas the function of most transcribed non-coding sequences remained unclear until recently. [1] [2] [3] It is now known that non-coding RNAs, including small (precursors <200 nucleotides in length) and long (>200 nucleotides in length) non-coding RNAs (lncRNAs), represent an important group of RNAs that are transcribed from the so-called genomic "dark matter". [4] [5] [6] Recent studies have demonstrated that lncRNAs play significant roles in diverse biological and pathological processes, such as transcriptional regulation, cell fate determination and tumorigenesis. [7] [8] [9] The importance of lncRNAs in cancer development can be exemplified by the frequent upregulation of the HOX antisense intergenic RNA (HOTAIR), 10 Colon Cancer Associated Transcript 1 (CCAT1) 11 and BRAF-regulated lncRNA 1 (BANCR) 12 in human cancers and their association with disease progression. Delineating the expression and functions of other lncRNAs is essential for understanding the molecular pathogenesis of cancer as well as for identifying novel molecular biomarkers for cancer diagnosis, prognostication and prediction of treatment response. [13] [14] [15] [16] SPRY4-IT1 (GenBank accession ID AK024556), a 708 bp lncRNA, was first discovered by Khaitan and colleagues in 2011.
17
SPRY4-IT1 is derived from an intron of SPRY4 gene resided on chromosome 5q31.3, which encodes an endogenous inhibitor of the receptor-transduced mitogen-activated protein kinase pathway. 17, 18 Computational prediction suggested its secondary structure of SPRY4-IT1 might contain several long hairpins. This lncRNA was originally reported to be highly upregulated in melanoma where it played an oncogenic role. 17 Since its discovery, a growing number of studies have reported the aberrant expression of SPRY4-IT1 in other cancer types, such as lung, breast, gastric, oesophageal and prostate cancers. [19] [20] [21] [22] [23] In this review, we examine current evidence on the deregulation and function of SPRY4-IT1 in human cancers IT1 expression has been shown to predict survival of cancer patients. In this review, we summarize recent evidence concerning SPRY4-IT1 deregulation and the associated mechanisms in human cancers. We also discuss the potential clinical utilization of this lncRNA as a diagnostic and prognostic biomarker for cancer patients.
( Table 1 and Figure 1 ). We also discuss the potential clinical utilities of SPRY4-IT1 as a biomarker.
| OS TEOSARCOMA
Xu et al. 24 measured the role of SPRY4-IT1 in the development of osteosarcoma. They firstly measured the expression of SPRY4-IT1
in the osteosarcoma cell lines and tissues. They found that the SPRY4-IT1 expression was upregulated in osteosarcoma cell lines and tissues. In addition, they showed that knockdown expression of SPRY4-IT1 suppressed the osteosarcoma cell growth through inducing G1 arrest and increasing cell apoptosis. Furthermore, SPRY4-IT1
inhibition expression suppressed osteosarcoma cell invasion and migration. These findings proved that SPRY4-IT1 acted as an oncogene in development of osteosarcoma.
| MEL ANOMA
SPRY4-IT1 was upregulated in human melanomas as compared with the normal melanocytes. 25, 26 There was also a strong correlation between SPRY4-IT1 and SPRY4 expression. 17 RNA-fluorescent in situ hybridization revealed that SPRY4-IT1 was predominantly expressed in the cytoplasm of melanoma cells, in which knockdown of SPRY4-IT1 decreased cell survival, proliferation, migration and invasion. 17 A subsequent study identified lipin 2, an enzyme that converts phosphatidate to diacylglycerol, as a major binding partner of SPRY4-IT1. 27 Knockdown of SPRY4-IT1 not only elevated the protein expression of lipin 2 but also increased the levels of diacylglycerol O-acyltransferase 2, an enzyme involved in the conversion of diacylglycerol to triacylglycerol. Consistently, SPRY4-IT1 knockdown increased the levels of several lipid species, including fatty acyl chains, acyl carnitine and triacylglycerol. These findings suggested that SPRY4-IT1 might alter lipid metabolism to induce lipotoxicity in melanoma cells through lipin 2.
| B RE A S T C AN CER
Shi and colleagues found that SPRY4-IT1 expression was significantly higher in breast cancer tissues as compared with normal tissues. 20 Increased SPRY4-IT1 expression was associated with larger tumour size and more advanced pathological stage. Further experiments demonstrated that the knockdown of SPRY4-IT1 significantly inhibited cell proliferation and induced apoptosis in breast cancer cell lines.
| OE SOPHAG E AL C AN CER
SPRY4-IT1 expression was significantly upregulated in oesophageal squamous cell carcinoma (ESCC) tissues and cell lines as compared with their normal counterparts. 28 In addition, higher SPRY4-IT1 expression predicted poorer prognosis and more advanced clinical stages. Multivariate analysis revealed that SPRY4-IT1 was an independent prognostic factor in patients with ESCC. Knockdown of SPRY4-IT1 not only reduced ESCC cell proliferation, invasiveness and migration in vitro but also ESCC xenograft growth in vivo.
Another study demonstrated that the plasma levels SPRY4-IT1 were significantly higher in ESCC patients than with normal controls. 29 These findings indicated that SPRY4-IT1 is involved in ESCC pathogenesis and may serve as a potential diagnostic and prognostic biomarker as well as a target for therapeutic intervention. 
| PROS TATE C AN CER
SPRY4-IT1 expression was higher in primary human prostatic adenocarcinomas and prostate cancer cell line PC3 as compared with matched normal tissues and normal prostate epithelial cells.
Functional investigation revealed that knockdown of SPRY4-IT1
reduced PC3 cell proliferation and invasion and promoted apoptosis. 
| LUNG C AN CER
The expression of SPRY4-IT1 was decreased in ~95% of cancer tissues compared with corresponding adjacent normal tissues in non-small-cell lung cancer (NSCLC). In addition, low SPRY4-IT1 expression was correlated with a poor prognosis in NSCLC patients independent of other clinicopathological parameters. Functional characterization revealed that SPRY4-IT1 inhibited lung cancer cell proliferation, migration and invasion, and promoted apoptosis. More importantly, ectopic overexpression of SPRY4-IT1 inhibited tumorigenesis and metastasis of NSCLC in vivo. 34 Contrary to the reported downregulation of SPRY4-IT1 in NSCLC tissues, another study demonstrated that the levels of circulating SPRY4-IT1 was significantly higher in NSCLC plasma samples, indicating that this lncRNA might serve as a potential predictive biomarker for the early diagnosis of NSCLC. 35 
| G A S TRI C C AN CER
Similar to lung cancer, the expression of SPRY4-IT1 in gastric cancer is controversial. One study reported that SPRY4-IT1 expression was downregulated in gastric cancer tissues as compared with normal tissues. Lower SPRY4-IT1 expression was also associated with larger tumour size and more advanced clinical and pathological stages and predicted shorter survival of gastric cancer patients. Further investigation showed that SPRY4-IT1 might suppress metastasis through the regulation of epithelial-mesenchymal transition (EMT) in gastric cancer. 21 However, another study showed that SPRY4-IT1 expression was upregulated in both gastric cancer tissues and cell lines. 36 Additionally, SPRY4-IT1 expression levels were positively correlated with advanced TNM stage and served as an independent prognostic indicator of overall survival and disease-free survival in gastric cancer patients. In vitro assays showed that the inhibition of SPRY4-IT1 decreased gastric cancer cell proliferation and migration, and invasion (Table 1) .
| CON CLUS I ON AND FUTURE PROS PEC TIVE
LncRNAs are important regulators of cellular processes. The lncRNA SPRY4-IT1 is upregulated in many cancer types, including breast,
TA B L E 1 SPRY4-IT1 expressions in human cancers

Cancer type Expression References
Lung cancer Downregulaed Upregulated (Serum) [34, 35] Osteosarcoma Upregulated [26] Gastric cancer Upregulated Downregulaed [21, 36] Breast cancer Upregulated [20] Oesophageal cancer Upregulated [28, 29] Prostate cancer Upregulated [32] Bladder cancer Upregulated [30] Melanoma Upregulated [24, 25, 27] Renal cancer Upregulated [31] Glioma Upregulated [33] oesophageal, prostate, bladder and renal cancers as well as melanoma and glioma. However, the expression of SPRY4-IT1 in NSCLC 
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